TEAM 2 – Jean-Philippe Collet – Atherothrombosis and Applied Pharmacology

TEAM 2 – Jean-Philippe Collet – Atherothrombosis and Applied Pharmacology

EQ2 JP Collet UMRS1166

J.-Ph. Collet, Team 2 Head

GOALS
The main goal of Team 2 is to improve knowledge in cardiovascular medicine from treatment strategies to education for primary prevention mainly in the field of atherothrombosis. Expanding of the group led to new areas of investigation including cardiovascular epidemiology, education technological innovations. Our cardiovascular research is broad going from in vitro experimental models to randomized clinical trials. It has always been focused on the same objectives, but projects have been diversified. The permanent interaction between clinicians and scientists within the same location is the major strength of the group. This unique set-up allows the attraction of fresh minds who volunteer for the challenge of clinical research. The development of new core lab facilities and our gained expertise in the field of clinical research via the ACTION study group are the key steps for a promising near future and facilitated interaction with basic science teams within UMRS_1166.

Action coeur JP Collet UMRS1166

See more: www.action-coeur.org

New models for experimental thrombosis
Demonstration of the pronostic role of biomarkers
Inflammation and cardiovascular disease
Myocarditis
Comparative evaluation of antithrombotic therapies
PK and PD models for drug evaluation
Phase 1 study for oral antithrombotic treatment
Use of metanalysis techniques
Cllinical and biological registries in atherothrombosis
Core laboratory for angiography and biology
Student tuition (Masters and PhD)
Randomized trials (www.action-coeur.org)

NamePositionEmailORCID

  1. Silvain, J, Kerneis, M, Zeitouni, M, Lattuca, B, Galier, S, Brugier, D et al.. Interleukin-1β and Risk of Premature Death in Patients With Myocardial Infarction. J Am Coll Cardiol. 2020;76 (15):1763-1773. doi: 10.1016/j.jacc.2020.08.026. PubMed PMID:32861811 .
  2. Lattuca, B, Bouziri, N, Kerneis, M, Portal, JJ, Zhou, J, Hauguel-Moreau, M et al.. Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. J Am Coll Cardiol. 2020;75 (14):1676-1685. doi: 10.1016/j.jacc.2020.01.057. PubMed PMID:32273033 .
  3. Lattuca, B, Silvain, J, Yan, Y, Pouillot, C, Cuisset, T, Cayla, G et al.. Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study. Circ Cardiovasc Interv. 2019;12 (11):e007749. doi: 10.1161/CIRCINTERVENTIONS.118.007749. PubMed PMID:31694410 .
  4. Collet, JP, Zeitouni, M, Procopi, N, Hulot, JS, Silvain, J, Kerneis, M et al.. Long-Term Evolution of Premature Coronary Artery Disease. J Am Coll Cardiol. 2019;74 (15):1868-1878. doi: 10.1016/j.jacc.2019.08.1002. PubMed PMID:31601367 .
  5. Salem, JE, Allenbach, Y, Vozy, A, Brechot, N, Johnson, DB, Moslehi, JJ et al.. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. N Engl J Med. 2019;380 (24):2377-2379. doi: 10.1056/NEJMc1901677. PubMed PMID:31189043 .
  6. Guerin, M, Silvain, J, Gall, J, Darabi, M, Berthet, M, Frisdal, E et al.. Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2018;72 (25):3259-3269. doi: 10.1016/j.jacc.2018.09.080. PubMed PMID:30573028 .
  7. Overtchouk, P, Guedeney, P, Rouanet, S, Verhoye, JP, Lefevre, T, Van Belle, E et al.. Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use: The FRANCE TAVI Registry. J Am Coll Cardiol. 2019;73 (1):13-21. doi: 10.1016/j.jacc.2018.08.1045. PubMed PMID:30153483 .
  8. Hauguel-Moreau, M, Boccara, F, Boyd, A, Salem, JE, Brugier, D, Curjol, A et al.. Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. Eur Heart J. 2017;38 (21):1676-1686. doi: 10.1093/eurheartj/ehw583. PubMed PMID:28065907 .
  9. Cayla, G, Cuisset, T, Silvain, J, Leclercq, F, Manzo-Silberman, S, Saint-Etienne, C et al.. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388 (10055):2015-2022. doi: 10.1016/S0140-6736(16)31323-X. PubMed PMID:27581531 .
  10. Montalescot, G, van 't Hof, AW, Lapostolle, F, Silvain, J, Lassen, JF, Bolognese, L et al.. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371 (11):1016-27. doi: 10.1056/NEJMoa1407024. PubMed PMID:25175921 .
  11. Montalescot, G, Rangé, G, Silvain, J, Bonnet, JL, Boueri, Z, Barthélémy, O et al.. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study. Circulation. 2014;129 (21):2136-43. doi: 10.1161/CIRCULATIONAHA.113.007524. PubMed PMID:24718568 .

Action coeur JP Collet UMRS1166

See www.action-coeur.org

Share This